Reshaping the Path of Mild Cognitive Impairment by Refining Exercise Prescription

January 25, 2024 updated by: Teresa Liu-Ambrose, University of British Columbia

Reshaping the Path of Mild Cognitive Impairment by Refining Exercise Prescription: Understanding Training Type and Exploring Mechanisms

Dementia is one of the most pressing health care issues of the 21st century. Evidence suggests that exercise enhances cognitive function in healthy older adults. Most research has focused on aerobic training (AT). Therefore, investigators aim to assess the individual effects of AT and resistance training (RT), as well as the interaction effect of combining the two types of exercise training, on cognitive function in older adults with mild cognitive impairment.

Study Overview

Detailed Description

Investigators will conduct a 6-month assessor-blinded randomized-controlled trial of 216 community-dwelling adults with mild cognitive impairment. Individuals will be randomized to one of four experimental groups, all which receive 6 months of exercise classes four times per week: 1) combined aerobic training and resistance training; 2) aerobic training; 3) resistance training; or 4) balance and toning exercise. There will be two measurement sessions: baseline and 6 months (end of intervention period). A 12-month followup (i.e., 18 months from baseline) measurement will be done for a sub-set of participants.

Study Type

Interventional

Enrollment (Estimated)

216

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1M9
        • University of British Columbia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years to 80 years (Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Community-dwelling in Metro Vancouver
  • Have subjective memory complaints, defined as the self-reported feeling of memory worsening with an onset within the last 5 years, as determined by interview and corroborated by an informant
  • Have a baseline Montreal Cognitive Assessment (MoCA) score < 26/30
  • Mini-Mental State Examination (MMSE) score = or > 22 at screening
  • Read, write, and speak English
  • Not expected to start or are stable on a fixed dose of anti-dementia medications (e.g., donepezil, galantamine, etc.) during the 6-month intervention period
  • Able to walk independently
  • Must be in sufficient health to participate in the exercise programs
  • Able to comply with scheduled visits, treatment plan, and other trial procedures
  • Provide a personally signed and dated informed consent document indicating that the individual (or a legally acceptable representative) has been informed of all pertinent aspects of the trial. In addition, an assent form will be provided at baseline and again at regular intervals

Exclusion Criteria:

  • Engaged in moderate (e.g., brisk walking) physical activity > 1 time per week, or > 60 minutes per week, in the 3 months prior to study entry
  • Diagnosed with dementia of any type
  • Clinically suspected to have neurodegenerative disease as the cause of mild cognitive impairment (MCI) that is not Alzheimer's Disease (AD), vascular cognitive impairment (VCI), or both (e.g., multiple sclerosis, Parkinson's disease, Huntington's disease, frontotemporal dementia)
  • At high risk for cardiac complications during exercise or unable to self-regulate activity or to understand recommended activity level; 5) have clinically important peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility, as determined by his/her family physician
  • Taking medications that may negatively affect cognitive function, such as anticholinergics, including agents with pronounced anticholinergic properties (e.g., amitriptyline), major tranquilizers (i.e., typical and atypical antipsychotics), and anticonvulsants (e.g., gabapentin, valproic acid)
  • On any hormone therapy (estrogen, progesterone, or testosterone) in the last 24 months
  • Planning to participate, or already enrolled in, a concurrent clinical drug or exercise trial

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Aerobic Training and Resistance Training (A&RT)
The A&RT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form.

Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).

To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.

Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).

To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.

Experimental: Aerobic Training (AT)
The AT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.

Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).

To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.

Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.

To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.

Experimental: Resistance Training (RT)
The RT program will be a four-times-per week program. Twice a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.

Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).

To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.

Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.

To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.

Active Comparator: Balance and Tone Program (CON)
The CON program will be a four-times-per week program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.

Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.

To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive function as measured by Alzheimer's Disease Assessment Scale Cognitive Subscale Plus (ADAS-Plus)
Time Frame: Baseline to 6 months
Cognition
Baseline to 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Executive functions as measured by standard neuropsychological and computerized tests
Time Frame: Baseline and 6 months and 18 months
Executive functions
Baseline and 6 months and 18 months
Cardiometabolic risk factors as measured by blood panel
Time Frame: Baseline and 6 months
Cardiometabolic risk factors
Baseline and 6 months
Health related quality of life as measured by the EuroQol five dimensions questionnaire (EQ-5D-5L)
Time Frame: Baseline, 3 months, 6 months, 12 months, and 18 months
Quality of life
Baseline, 3 months, 6 months, 12 months, and 18 months
Health related quality of life as measured by the ICE-CAP
Time Frame: Baseline, 3 months, 6 months, 12 months, and 18 months
Quality of life
Baseline, 3 months, 6 months, 12 months, and 18 months
Mood as measured by the Center for Epidemiologic Studies Depression Scale (CES-D)
Time Frame: Baseline and 6 months
Depressive symptoms
Baseline and 6 months
Brain function as measured by functional magnetic resonance imaging (fMRI)
Time Frame: Baseline and 6 months
Brain function
Baseline and 6 months
Brain structure as measured by structural magnetic resonance imaging
Time Frame: Baseline and 6 months
Brain structure
Baseline and 6 months
White matter lesion volume as measured by magnetic resonance imaging
Time Frame: Baseline and 6 months
White matter lesion
Baseline and 6 months
Diffusion tensor imaging as measured by magnetic resonance imaging
Time Frame: Baseline and 6 months
White matter integrity
Baseline and 6 months
Memory as measured by standard neuropsychological and computerized tests
Time Frame: Baseline and 6 months and 18 months
Memory
Baseline and 6 months and 18 months
Visualspatial ability as measured by standard neuropsychological and computerized tests
Time Frame: Baseline and 6 months
Visualspatial ability
Baseline and 6 months
Cardiorespiratory capacity as measured by treadmill test
Time Frame: Baseline and 6 months
Cardiovascular fitness
Baseline and 6 months
Mobility as measured by 400-m walk
Time Frame: Baseline and 6 months and 18 months
Mobility
Baseline and 6 months and 18 months
Cardiometabolic risk as measured by waist to hip ratio
Time Frame: Baseline and 6 months and 18 months
Cardiometabolic risk
Baseline and 6 months and 18 months
Cardiometabolic risk as measured by body mass index
Time Frame: Baseline and 6 months and 18 months.
Cardiometabolic risk
Baseline and 6 months and 18 months.
Cardiometabolic risk as measured by pulse wave velocity (arterial stiffness)
Time Frame: Baseline and 6 months
Cardiometabolic risk
Baseline and 6 months
Lower body strength as measured by Biodex
Time Frame: Baseline and 6 months
Lower body strength
Baseline and 6 months
Upper body strength as measured by grip strength
Time Frame: Baseline and 6 months
Upper body strength
Baseline and 6 months
Sleep quality as measured by Motion Watch actigraphy
Time Frame: Baseline and 6 months
Sleep quality
Baseline and 6 months
Neurotrophic factors as measured by blood
Time Frame: Baseline and 6 months
Neurotrophic factors
Baseline and 6 months
Mobility as measured by Short Physical Performance Battery
Time Frame: Baseline and 6 months and 18 months
Mobility
Baseline and 6 months and 18 months
Community mobility as measured by the Life Space Questionnaire
Time Frame: Baseline, 3 months, 6 months, 12 months, and 18 months
Mobility
Baseline, 3 months, 6 months, 12 months, and 18 months
Body composition as measured by DXA
Time Frame: Baseline and 6 months
Body composition
Baseline and 6 months
Loneliness as measured by the UCLA Loneliness Scale
Time Frame: Baseline and 6 months
Loneliness
Baseline and 6 months
Cognitive function as measured by Alzheimer's Disease Assessment Scale Cognitive Subscale - 13 items
Time Frame: Baseline and 6 months and 18 months
Cognitive function
Baseline and 6 months and 18 months
Sedentary behaviour as measure by the Sedentary Behaviour Questionnaire
Time Frame: Baseline, 3 months, 6 months, 12 months, and 18 months
Sedentary behaviour
Baseline, 3 months, 6 months, 12 months, and 18 months
Risk of sleep apnea as measured by the STOP Bang Questionnaire
Time Frame: Baseline and 6 months
Sleep apnea risk
Baseline and 6 months
Prospective falls via Monthly Calendars
Time Frame: Baseline and 3 months and 6 months and monthly
Accidental falls
Baseline and 3 months and 6 months and monthly
Social support as measured by Social Provision Scale
Time Frame: Baseline and 6 months
Social support
Baseline and 6 months
Mindfulness as measured by the Mindfulness Attention Awareness Scale
Time Frame: Baseline and 6 months
Mindfulness
Baseline and 6 months
Memory as measured by the Everyday Memory Questionnaire
Time Frame: Baseline and 6 months
Memory
Baseline and 6 months
Sleep as measured by the Pittsburgh Sleep Quality Index
Time Frame: Baseline, 6 months, 12 months, and 18 months
Sleep
Baseline, 6 months, 12 months, and 18 months
Functional ability as measured by the Lawson IADL
Time Frame: Baseline and 6 months
Instrumental activities of daily living
Baseline and 6 months
Comorbidities as measured by the Function Comorbidity Index
Time Frame: Baseline, 6 months, 12 months, and 18 months
Chronic conditions
Baseline, 6 months, 12 months, and 18 months
Mood as measured by the State and Trait Anxiety Inventory
Time Frame: Baseline and 6 months and 18 months
Mood
Baseline and 6 months and 18 months
Social network as measured by Lubben Social Network Scale
Time Frame: Baseline and 6 months
Social network
Baseline and 6 months
Physical activity as measured by the CHAMP Questionnaire
Time Frame: Baseline and 3 months and 6 months and monthly
Physical Activity Level
Baseline and 3 months and 6 months and monthly
ADAS-Cog Plus
Time Frame: 18 months
Cognitive function
18 months
Verbal memory and learning using the Rey Auditory Verbal Learning Test
Time Frame: Baseline, 6 months, and 18 months
Verbal memory and learning
Baseline, 6 months, and 18 months
Verbal fluency (categorial of animals and semantic using F,A,S)
Time Frame: Baseline, 6 months, and 18 months
Verbal functioning tests requiring retrieval
Baseline, 6 months, and 18 months
Cytokines - proteins involved in immune response, as measured by blood
Time Frame: Baseline and 6 months
Cytokines
Baseline and 6 months
Dual-task gait using Gaitrite
Time Frame: Baseline and 6 months
Dual-task walking
Baseline and 6 months
Health resource utilization (e.g., access health system services/resources)
Time Frame: Baseline, 3 months, and 6 months
Access health system services/resources
Baseline, 3 months, and 6 months
Physical activity level (i.e., amount of light, moderate, and vigorous) measured by Motion Watch actigraphy
Time Frame: Baseline and 6 months
Physical activity levels
Baseline and 6 months
Sedentary behaviour (i.e., less than = or less than1.5 mets of activity) measured by Motion Watch actigraphy
Time Frame: Baseline and 6 months
Sedentary behaviour
Baseline and 6 months
Quality of life measured by EQ-5D-5L
Time Frame: Baseline, 3 months, 6 months, and 18 months
Quality of life
Baseline, 3 months, 6 months, and 18 months
Wellbeing measured by ICE-CAP
Time Frame: Baseline, 3 months, 6 months, and 18 months
Wellbeing
Baseline, 3 months, 6 months, and 18 months
Cortisol levels through saliva samples (subset)
Time Frame: 5 times from baseline to 6 months
Cortisol levels
5 times from baseline to 6 months
Lower body strength as measured by the 30 sec sit-to-stand (subset)
Time Frame: Baseline and 6 months and 18 months
Lower body strength
Baseline and 6 months and 18 months
Telemere length
Time Frame: Baseline and 6 months
Marker of aging
Baseline and 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Lara Boyd, PhD, University of British Columbia
  • Principal Investigator: Liisa Galea, PhD, University of British Columbia
  • Principal Investigator: Alexander MacKay, PhD, University of British Columbia
  • Principal Investigator: Claudia Jacova, PhD, Pacific University
  • Principal Investigator: Arthur Kramer, PhD, Northeastern University
  • Principal Investigator: Joel Singer, PhD, University of British Columbia
  • Principal Investigator: Lindsay Nagamatsu, PhD, Western University
  • Principal Investigator: Teresa Liu-Ambrose, PhD, PT, University of British Columbia
  • Principal Investigator: John Best, PhD, University of British Columbia
  • Principal Investigator: Jennifer Davis, PhD, University of British Columbia
  • Principal Investigator: Charlie Goldsmith, PhD, Simon Fraser University
  • Principal Investigator: Ging-Yuek Robin Hsiung, MD, PhD, University of British Columbia
  • Principal Investigator: Michelle Voss, PhD, University of Iowa
  • Principal Investigator: Cindy Barha, PhD, University of British Columbia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 13, 2017

Primary Completion (Estimated)

December 1, 2024

Study Completion (Estimated)

July 1, 2025

Study Registration Dates

First Submitted

April 11, 2016

First Submitted That Met QC Criteria

April 11, 2016

First Posted (Estimated)

April 14, 2016

Study Record Updates

Last Update Posted (Actual)

January 26, 2024

Last Update Submitted That Met QC Criteria

January 25, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • H15-02181

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mild Cognitive Impairment

Clinical Trials on Aerobic Training

3
Subscribe